by GMFH Editing Team
Important scientific progress has been made in 2019 in our understanding of the contribution of gut microbiome in health and disease. Have a look at this “2019 Year at a glance” report and discover the year’s breakthroughs in the field.
by Andreu Prados
Genes aren’t the only culprit behind the current dramatic rise in colorectal cancer prevalence. Two new articles in Nature Medicine reveal specific microbial signatures for colorectal cancer, with potential use as candidates for developing non-invasive colorectal cancer screening.
by Andreu Prados
The induction of intestinal CD8 T cells has been involved in the efficacy of cancer immunotherapy. New work has identified 11 bacterial strains that enhance resistance to Listeria infection and improve the antitumor efficacy of checkpoint inhibitors in mice.
In 2018, the Gut Microbiota for Health (GMFH) digital community has reached an audience that includes scientists, healthcare professionals, and the general public, with 60,000 visits every month from all over the world. These changes reflect an increased awareness of
by Heather Galipeau
Mutations that lead to an impairment of tet methylcytosine dioxygenase 2 (Tet2) function or/and expression - a gene that encodes an epigenetic modifier enzyme - have been related to the development of haematopoietic malignancies in both mice and humans. According
by Andreu Prados
Mice models are widely used to assess the impact of exposure to environmental factors such as chemicals, drugs or infectious agents on host homeostasis through modulation of the gut microbiota. A new study, led by Dr. Guodong Zhang from the
by Andreu Prados
Recent research has found an association between colorectal cancer (CRC) and variations in the gut microbiome composition. Although mice research supports the theory that tumor development appears to be driven by interactions between the gut microbiome and host genomics, mechanisms
by Andreu Prados
Recent research has pointed to the role of gut microbiota-host interactions in the effectiveness of immunotherapeutic agents (here; here). However, little is known regarding the potential role of the gut microbiota in the immune-mediated effects of drugs used as cancer
The 7th Gut Microbiota for Health (GMFH) World Summit is set to be held in Rome, Italy, on March 10th and 11th, 2018! The event is co-organized by the Gut Microbiota & Health section of the European Society of Neurogastroenterology
by Andreu Prados
Previous research has shown that the human gut microbiota may mediate suppression of carcinogenesis through its interaction with host immunity. Among cancer types, colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death